Orshe

Less than two years ago, in a move analysts called “surprising” and “abrupt,” Boston Scientific said Ray Elliott would take over as CEO.

Today Elliott again surprised investors — by announcing his plans to retire at the end of the year. Boston Scientific shares fell on the news, and were down more than 9% to $6.99 in late trading.

The head of Eli Lilly’s research into Alzheimer’s disease, schizophrenia and other neurological diseases is unexpectedly leaving the company.

David Bredt’s last day at the drug maker is Feb. 25, a company spokeswoman says. He had joined Lilly in 2004.

Fellow industry drug researchers expressed surprise at the news, especially since Bredt had given no indication of his plans at recent events.

Skin types at the fair end of the spectrum are more susceptible to the burning rays of the sun — and to a higher risk for cancers and premature aging of the skin. But a little sun exposure also releases endorphins and gives us needed vitamin D. WSJ’s Melinda Beck and Laura Landro debate how good or bad the sun is for you on the News Hub.

Read the original post:  News Hub: The Sun and Your Health/a>

On the 50th anniversary of the pill, WSJ’s Melinda Beck tells Simon Constable on the News Hub what’s new in birth control. There are more options than ever, but despite all the choices, some three million U.S. women have an unplanned pregnancy ever year.

Go here to read the rest:  News Hub: First 50 Years of ‘The Pill’/a>

The symptoms of adult Attention Deficit Disorder — impatience, irritability, lateness and procrastination — sound like half the people in New York. So, how can you or a loved one might be one of the eight million adults who have it? WSJ’s Melinda Beck joins the News Hub to discuss.

Here is the original: News Hub: Got Adult Attention Deficit Disorder?/a>

The U.S. Chamber of Commerce plans to spend $50 million this summer and fall to sway election outcomes around the issue. Janet Adamy joins the News Hub to discuss.

Go here to see the original:  News Hub: Chamber Moves to Blunt Health Overhaul/a>

The pharmaceutical industry stands to gain with the passage of the health bill, while the insurance industry has mixed results, Stefanie Ilgenfritz reports on the News Hub.

Read more from the original source:  News Hub: Who Wins, Loses in Health Overhaul?/a>

After the health bill passed the House, new questions now emerge, including whether opposition to the bill will cede over time, WSJ executive Washington editor Jerry Seib reports on the News Hub.

Read more from the original source:  AM Report: Health Bill Passes/a>

In what could be his last public appeal for health-care legislation before a critical House vote, President Barack Obama says Congress is in position to end a century-long struggle over health care by passing his sweeping overhaul. Plus, the Dow finishes lower for the first time in nine sessions; and WSJ’s Amy Chozick joins the News Hub to tell us why a crop of shows with dysfunctional leading women has given Showtime a burst of momentum.

As Democrats approach a deal for passing the health bill, Republicans are saying that getting the bill past the Senate is not a given, Peter Landers reports on the News Hub.

More here:  News Hub: Republicans Plan to Skewer Health Bill/a>